共 387 条
[31]
Burki HR(1995)Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans Movement Disord 10 28-88
[32]
Fuller RW(1996)Comparative review of dopamine receptor agonists in Parkinson’s disease CNS Drugs 5 369-6
[33]
Clemens JA(1988)Pleuropulmonary disease during bromocriptine treatment of Parkinson’s disease Arch Intern Med 148 2231-30
[34]
Jenner P(1986)Bromocriptine-induced pleuropulmonary fibrosis Thorax 41 328-9
[35]
Vermeulen RJ(1995)Retroperitoneal fibrosis in a patient with Parkinson’s disease treated with pergolide Clin Neuropharmacol 18 277-81
[36]
Drukarch B(1999)Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide J Neurol Neurosurg Psychiatry 66 79-5
[37]
Wolters EC(1992)Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline Eur Respir J 5 263-5
[38]
Cagnotto A(1999)Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson’s disease Mayo Clin Proc 74 371-62
[39]
Parotti L(1983)Fate and disposition of bromocriptine in animals and man. II: absorption, elimination and metabolism Eur J Drug Metab Pharmacokinet 8 51-39
[40]
Mennini T(1980)The pharmacokinetics of bromocriptine in man Adv Biochem Psychopharmacol 23 125-41